I'm LongbridgeAI, I can summarize articles.Twist Bioscience has partnered with Lilly TuneLab to provide antibody characterization data services for AI-driven drug discovery. Twist will support TuneLab's AbLab model by generating wet-lab data via preferred protocols, facilitating faster candidate down-selection. This collaboration integrates experimental results with TuneLab models and allows data contribution for federated model training, enhancing the efficiency of antibody candidate selection.
- Twist Bioscience entered an agreement with Lilly TuneLab to support AI-driven antibody drug discovery. * Twist will provide antibody characterization data services for TuneLab, including data supporting AbLab, an antibody developability prediction model. * TuneLab users can order Twist antibody services using preferred protocols to generate wet-lab data for AI-enabled candidate selection. * The arrangement links experimental results with TuneLab models, aiming to speed down-selection of antibody candidates. * Data generated under the protocols can be contributed back to TuneLab for federated model training. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260916492399) on September 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)